Inhibin isolated from ovarian follicular fluid
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 7, 1992
Issued Date -
N/A
app pub date -
Apr 11, 1989
filing date -
Jun 8, 1984
priority date (Note) -
Expired
status (Latency Note)
![]() |
A preliminary load of PAIR data current through [] has been loaded. Any more recent PAIR data will be loaded within twenty-four hours. |
PAIR data current through []
A preliminary load of cached data will be loaded soon.
Any more recent PAIR data will be loaded within twenty-four hours.
![]() |
Next PAIR Update Scheduled on [ ] |

Importance

US Family Size
|
Non-US Coverage
|
Patent Longevity
|
Forward Citations
|
Abstract
A protein which satisfies all the biological criteria which are characteristic of inhibin has been isolated from a gonadal source. The purification and characterization of inhibin and the use of the purified material to raise antibodies, the use of inhibin and said antisera in a quantative radioimmunoassay, and applications in vitro and in vivo of inhibin and antibody to inhibin, are described. There is provided a purified protein, inhibin, characterised in that a. the apparent molecular weight as determined by SDS-PAGE is 56,000.+-.1,000 b. the isoelectric point is in the range 6.9-7.3 c. the protein can bind specifically to Concanavalin A-Sepharose d the protein consists of two sub-units, characterized in that i. their apparent molecular weights as determined by SDS-PAGE are 44,000.+-.3,000 and 14,000.+-.2,000 respectively. ii. the isoelectric point of the 44,000 molecular weight sub-unit is in the range 6.0-7.0 iii. the N-terminal amino acid sequences of the two sub-units are as described herein e. the protein can suppress follicle stimulating hormone (FSH) but not luteinising hormone (LH), thyroid stimulating hormone or prolactin in an in vitro bioassay system f. the protein can be labeled with radioactive iodine. There is also provided a method for isolating and purifying inhibin from mammalian ovarian follicular fluid, characterised by a. one or more gel permeation chromatography steps; b. one or more reversed-phase high performance liquid chromatography steps; c. one or more preparative polyacrylamide gel electrophoresis steps; d. Electrophoretic elution of the purified inhibin.

First Claim
Family

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Patent Owner(s)
Patent Owner | Address | |
---|---|---|
MONASH UNIVERSITY | CLAYTON | |
ST VINCENT'S INSTITUTE OF MEDICAL RESERACH | 41 VICTORIA PARADE FITZROY VICTORIA 3065 | |
BIOTECHNOLOGY AUSTRALIA PTY LTD | EAST ROSEVILLE NSW 2069 | |
MONASH MEDICAL CENTRE | ST KILDA ROAD MELBOURNE VICTORIA 3004 |
International Classification(s)

- [Classification Symbol]
- [Patents Count]
Inventor(s)
Inventor Name | Address | # of filed Patents | Total Citations |
---|---|---|---|
Burger, Henry G | East Melbourne, AU | 3 | 36 |
de, Kretser David M | Surrey Hills, AU | 4 | 43 |
Findlay, John K | Mont Albert, AU | 2 | 34 |
Forage, Robert G | New South Wales, AU | 2 | 34 |
Hearn, Milton T W | Balwyn, AU | 11 | 403 |
Milne-Robertson, David | Glen Waverley, AU | 1 | 30 |
Morgan, Francis J | North Fitzroy, AU | 2 | 34 |
Weitenhall, Richard E H | New South Wales, AU | 1 | 30 |
Cited Art Landscape
- No Cited Art to Display

Patent Citation Ranking
Forward Cite Landscape
- No Forward Cites to Display

Maintenance Fees
Fee | Large entity fee | small entity fee | micro entity fee | due date |
---|
Fee | Large entity fee | small entity fee | micro entity fee |
---|---|---|---|
Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |
Full Text

Legal Events

Matter Detail

Renewals Detail

Note
The template below is formatted to ensure compatibility with our system.
Provide tags with | separated like (tags1|tags2).
Maximum length is 128 characters for Customer Application No
Mandatory Fields * - 'MatterType','AppType','Country','Title','SerialNo'.
Acceptable Date Format - 'MM/DD/YYYY'.
Acceptable Filing/App Types -
- Continuation/Divisional
- Original
- Paris Convention
- PCT National
- With Priority
- EP Validation
- Provisional Conversion
- Reissue
- Provisional
- Foreign Extension
Acceptable Status -
- Pending
- Abandoned
- Unfiled
- Expired
- Granted
Acceptable Matter Types -
- Patent
- Utility Model
- Supplemental Protection Certificate
- Design
- Inventor Certificate
- Plant
- Statutory Invention Reg
Advertisement
Advertisement
Advertisement

Recipient Email Address

Recipient Email Address

Comment
Recipient Email Address

Success
E-mail has been sent successfully.
Failure
Some error occured while sending email. Please check e-mail and try again!
PAIR load has been initiated
A preliminary load of cached data will be loaded soon. Current PAIR data will be loaded within twenty four hours.
File History PDF
Thank you for your purchase! The File Wrapper for Patent Number 5102807 will be available within the next 24 hours.
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:

Last Refreshed On:
Changes done successfully
Important Notes on Latency of Status data
Please note there is up to 60 days of latency in this Status indicator for certain status conditions. You can obtain up-to-date Status indicator readings by ordering PAIR for the file.
An application with the status "Published" (which means it is pending) may be recently abandoned, but not yet updated to reflect its abandoned status. However, an application filed less than one year ago is unlikely to be abandoned.
A patent with the status "Granted" may be recently expired, but not yet updated to reflect its expired status. However, it is highly unlikely a patent less than 3.5 years old would be expired.
An application with the status "Abandoned" is almost always current, but there is a small chance it was recently revived and the status not yet updated.
Important Note on Priority Date data
This priority date is an estimated earliest priority date and is purely an estimation. This date should not be taken as legal conclusion. No representations are made as to the accuracy of the date listed. Please consult a legal professional before relying on this date.
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.